{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:22Z","timestamp":1790983102174,"version":"4.1.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple M overlap syndrome is a rare, but often fatal, immune-related adverse event. Evidence on the effectiveness of immunosuppressive treatments, including abatacept, and disease monitoring in complex cases remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary<\/jats:title>\n                    <jats:p>A man in his 60s developed fulminant immune checkpoint inhibitor (ICI)-related myocarditis after nivolumab plus ipilimumab for recurrent lung adenocarcinoma, complicated by triple M overlap syndrome (myocarditis, myositis, and myasthenia gravis). Despite high-dose corticosteroids and intravenous immunoglobulin, cardiac biomarkers worsened, with progressive conduction abnormalities and a rapid decline in the left ventricular ejection fraction to 23%. Upon transfer to our institution, he developed sustained ventricular tachycardia, requiring direct current cardioversion and intra-aortic balloon pump support. Endomyocardial biopsy (EMB) at admission showed CD8+ T-cell-predominant myocarditis, consistent with a fulminant, steroid-refractory disease course. Abatacept was initiated after a multidisciplinary discussion, resulting in haemodynamic and arrhythmic stabilization. Guided by serial EMB findings of residual myocardial inflammation, abatacept was administered four times by hospital Day 30, along with intravenous methylprednisolone pulse therapy, plasma exchange, intravenous immunoglobulin, and tacrolimus. Left ventricular ejection fraction gradually improved to 56%, and a follow-up EMB on Day 88 demonstrated marked histopathological recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case illustrates that abatacept-based multidisciplinary therapy may help stabilize fulminant steroid-refractory ICI-related myocarditis with triple M overlap syndrome. Serial EMB provided a histopathological assessment of residual myocardial inflammation and guided immunosuppressive therapy, suggesting a potential role for serial biopsy in complex cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytag620","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:48:38Z","timestamp":1787312918000},"source":"Crossref","is-referenced-by-count":1,"title":["Abatacept for steroid-refractory fulminant immune checkpoint inhibitor myocarditis with triple M overlap syndrome: a case report with serial endomyocardial biopsy assessment"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8031-6202","authenticated-orcid":false,"given":"Ruriko","family":"Matsui","sequence":"first","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tennodai, Tsukuba, 3058575 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-7770","authenticated-orcid":false,"given":"Kimi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tennodai, Tsukuba, 3058575 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-1008","authenticated-orcid":false,"given":"Kazuko","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Cancer Center Hospital \u00a0 East, Kashiwanoha, Kashiwa, 2778577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-899X","authenticated-orcid":false,"given":"Tomoko","family":"Ishizu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba , Tennodai, Tsukuba, 3058575 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"2026083006311880300_ytag620-B1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026083006311880300_ytag620-B2","article-title":"Triple M overlap syndrome: myocarditis, myositis and myasthenia Gravis after a single administration of pembrolizumab","volume":"17","author":"Baptista","year":"2025","journal-title":"Cureus"},{"key":"2026083006311880300_ytag620-B3","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026083006311880300_ytag620-B4","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026083006311880300_ytag620-B5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"2026083006311880300_ytag620-B6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"2026083006311880300_ytag620-B7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"2026083006311880300_ytag620-B8","doi-asserted-by":"crossref","first-page":"e004699","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026083006311880300_ytag620-B9","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"2026083006311880300_ytag620-B10","article-title":"Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report","volume":"9","author":"Wadden","year":"2025","journal-title":"Eur Heart J Case Rep"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/9\/ytag620\/70826871\/ytag620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/9\/ytag620\/70826871\/ytag620.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T10:31:22Z","timestamp":1788085882000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytag620\/8772248"}},"subtitle":[],"editor":[{"given":"Giacomo Tini","family":"Melato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Linda","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytag620","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,27]]},"article-number":"ytag620"}}